CSF2 and congenital rubella syndrome: Sterner et al. have demonstrated that GM-CSF neutralization with lenzilumab and GM-CSF knockout in CAR-T cells interrupted CAR-T cell-induced monocyte activation as well as subsequent IL1β and IL6 production, thereby preventing CRS and neuro-inflammation (32).